DK1066041T3 - Use of 17-alpha-estradiol derivatives for the therapy of side effects during and / or after a GnRHa therapy - Google Patents
Use of 17-alpha-estradiol derivatives for the therapy of side effects during and / or after a GnRHa therapyInfo
- Publication number
- DK1066041T3 DK1066041T3 DK99907318T DK99907318T DK1066041T3 DK 1066041 T3 DK1066041 T3 DK 1066041T3 DK 99907318 T DK99907318 T DK 99907318T DK 99907318 T DK99907318 T DK 99907318T DK 1066041 T3 DK1066041 T3 DK 1066041T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapy
- alpha
- side effects
- gnrha
- estradiol
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 150000000304 17α-estradiols Chemical class 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Chemical class OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 1
- 229930182834 17alpha-Estradiol Natural products 0.000 abstract 1
- VOXZDWNPVJITMN-SFFUCWETSA-N 17α-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-SFFUCWETSA-N 0.000 abstract 1
- 150000000307 17β-estradiols Chemical class 0.000 abstract 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229960001348 estriol Drugs 0.000 abstract 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical class OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract 1
- 238000007918 intramuscular administration Methods 0.000 abstract 1
- 238000007912 intraperitoneal administration Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the use of at least one active agent from the following group: 17 alpha -estradiol, its chemically modified derivatives and chemically modified derivatives of 17 beta -estradiol or estriol; for producing pharmaceutical preparations for treating side effects such as hot flushes during and/or after a treatment with analogs or antagonists of the gonadotropin-releasing hormone (GnRHa-therapy). Said pharmaceutical preparations can be produced in oral and parenteral, including topical, rectal, sub-cutaneous, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal or sub-lingual forms of administration.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19815060A DE19815060A1 (en) | 1998-04-03 | 1998-04-03 | Pharmaceutical preparations for the treatment of side effects during and / or after GnRHa therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1066041T3 true DK1066041T3 (en) | 2006-03-27 |
Family
ID=7863548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99907318T DK1066041T3 (en) | 1998-04-03 | 1999-02-10 | Use of 17-alpha-estradiol derivatives for the therapy of side effects during and / or after a GnRHa therapy |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1066041B1 (en) |
| JP (1) | JP3925688B2 (en) |
| AT (1) | ATE308986T1 (en) |
| AU (1) | AU2712799A (en) |
| DE (2) | DE19815060A1 (en) |
| DK (1) | DK1066041T3 (en) |
| ES (1) | ES2252931T3 (en) |
| WO (1) | WO1999051243A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19906159A1 (en) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-hydroxyestratrienes as selectively active estrogens |
| WO2005063276A1 (en) * | 2003-12-23 | 2005-07-14 | Debiopharm S.A. | Methods and compositions using gonadotropin hormone releasing hormone |
| WO2018060501A2 (en) | 2016-09-30 | 2018-04-05 | Myovant Sciences Gmbh | Methods of treating uterine fibroids and endometriosis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
| US5043331A (en) * | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
| US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
| AR246186A1 (en) * | 1989-11-17 | 1994-07-29 | Beta Pharm Co | Procedure for manufacturing a device for administering stradiol through the skin. |
| ATE153345T1 (en) * | 1990-03-16 | 1997-06-15 | Applied Research Systems | TREATMENT OF POLYCYSTIC OVAL DISEASE |
| AU8166191A (en) * | 1990-08-10 | 1992-02-13 | Ortho Pharmaceutical Corporation | Method for treatment of bone wasting diseases |
| US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
| EA000992B1 (en) * | 1995-12-14 | 2000-08-28 | Мерк Энд Ко., Инк. | Antagonists of gonadotropin releasing hormone |
-
1998
- 1998-04-03 DE DE19815060A patent/DE19815060A1/en not_active Withdrawn
-
1999
- 1999-02-10 ES ES99907318T patent/ES2252931T3/en not_active Expired - Lifetime
- 1999-02-10 EP EP99907318A patent/EP1066041B1/en not_active Expired - Lifetime
- 1999-02-10 DK DK99907318T patent/DK1066041T3/en active
- 1999-02-10 AU AU27127/99A patent/AU2712799A/en not_active Abandoned
- 1999-02-10 WO PCT/DE1999/000355 patent/WO1999051243A1/en not_active Ceased
- 1999-02-10 JP JP2000542014A patent/JP3925688B2/en not_active Expired - Fee Related
- 1999-02-10 AT AT99907318T patent/ATE308986T1/en not_active IP Right Cessation
- 1999-02-10 DE DE59912770T patent/DE59912770D1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1066041B1 (en) | 2005-11-09 |
| ATE308986T1 (en) | 2005-11-15 |
| EP1066041A1 (en) | 2001-01-10 |
| ES2252931T3 (en) | 2006-05-16 |
| JP2002510637A (en) | 2002-04-09 |
| DE59912770D1 (en) | 2005-12-15 |
| DE19815060A1 (en) | 1999-10-14 |
| WO1999051243A1 (en) | 1999-10-14 |
| AU2712799A (en) | 1999-10-25 |
| JP3925688B2 (en) | 2007-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE215081T1 (en) | GONADOTROPIN RELEASING HORMONE ANTAGONISTS | |
| NO20040968L (en) | Opioid agonist preparations with releasable and sequestered antagonist | |
| PL357944A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| NZ325060A (en) | Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone | |
| NZ326331A (en) | Heterocycle-condensed morphinoid derivatives and medicaments | |
| DK1135153T3 (en) | Uses of EPH receptor antagonists and agonists for the treatment of vascular disorders | |
| ATE486840T1 (en) | MODIFIED FORMS OF PHARMACEUTICALLY ACTIVE AGENTS AND USES THEREOF | |
| MX9804850A (en) | Antagonists of gonadotropin releasing hormone. | |
| TR200201874T2 (en) | New compounds and compositions as protease inhibitors. | |
| BR0112160A (en) | Glucocorticoid Selective Anti-Inflammatory Agents | |
| MY129356A (en) | Electrospun pharmaceutical compositions | |
| TR199901669T2 (en) | Required dosage forms and method for the treatment of erectile dysfunction in men. | |
| ATE254927T1 (en) | ANTAGONISTS OF ENDOTHELIAL ACTION | |
| DE69932510D1 (en) | VASKULARISIERUNGSINHIBITOREN | |
| ATE272628T1 (en) | SUBSTITUTED GAMMA-PHENYL-DELTA-LACTONES AND ANALOGUES THEREOF, AND USES THEREOF | |
| ATE248832T1 (en) | ANTAGONISTS OF GONADOTROPIN-RELEASE HORMON | |
| DE69927582D1 (en) | NEW ANALOG OF 16-HYDROXYEICOSATETRAIC ACID | |
| DK1066041T3 (en) | Use of 17-alpha-estradiol derivatives for the therapy of side effects during and / or after a GnRHa therapy | |
| ES2162433T3 (en) | PROCEDURE FOR THE TREATMENT OF THE CEMENT CLINKER. | |
| CO5251423A1 (en) | TREATMENT OF ENDOMETRIOSIS OR INFERTILITY, OR IMPROVEMENT OF FERTILITY | |
| MY126321A (en) | Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer. | |
| PT1066304E (en) | LHRH MACROLID ANTAGONISTS | |
| BR0116552A (en) | Amlodipine hemi maleate, process, method for the treatment or prevention of angina or hypertension, pharmaceutical composition for use in the treatment and / or of angina or hypertension | |
| DK1265856T3 (en) | The novel process for the preparation of alpha (2,4-disulfophenyl) -N-tert-butylnitrone and pharmaceutically acceptable salts thereof | |
| BR0102150A (en) | Isoxazole-sulfonamides endothelin antagonists |